Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Severe HTN unresponsive to standard therapy In conjunction w/ a β-blocker or methyldopa, and a diuretic: Initial: 5 mg/day, increase gradually at intervals of at least 3 days up to 40 mg or 50 mg as a single or in 2 divided doses daily. Max: 100 mg/day. For rapid control of BP: Dose increments of 5 mg 6 hrly may be given. Topical Male pattern baldness Male: As 2% or 5% soln: Apply 1 mL bid. As 5% foam or aerosol: Apply ½ capful bid. Female: As 2% soln: Apply 1 mL bid. As 5% foam or aerosol: Apply ½ capful once daily.
May be taken with or without food.
Phaeochromocytoma. Topical: Patient w/ treated or untreated HTN, scalp abnormality (e.g. psoriasis, sunburn), shaved scalp.
Special Precautions
Patient w/ pulmonary HTN, angina pectoris, chronic heart failure, recent MI. Renal impairment. Elderly, childn. Pregnancy and lactation. Monitoring Parameters Monitor BP, fluid and electrolytes, body wt, signs/symptoms of pericardial effusion, renal function.
Adverse Reactions
Reflex tachycardia, fluid retention, changes in ECG, hypertrichosis, pericardial effusion and tamponade, pericarditis, exacerbation of angina pectoris, headache, nausea, gynaecomastia, breast tenderness, polymenorrhoea, allergic rashes, Stevens-Johnson syndrome. Rarely, thrombocytopenia and leucopenia. Topical: Contact dermatitis, pruritus, local burning, flushing, changes in hair colour or texture.
Drug Interactions
Additive effect w/ other hypotensive drugs. Risk of orthostatic hypotension w/ sympathetic blocking drugs (e.g. guanethidine). Topical: Enhanced absorption w/ other topical medical preparations (e.g. corticosteroids, retinoids or occlusive ointment bases).
ATC Classification
D11AX01 - minoxidil ; Belongs to the class of other dermatologicals.
C02DC01 - minoxidil ; Belongs to the class of pyrimidine derivative agents acting on arteriolar smooth muscle. Used in the treatment of hypertension.
Disclaimer: This information is independently developed by CIMS based on minoxidil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in